Background/Aims: We investigated the role of dimethyloxalylglycine (DMOG) in bone marrow mesenchymal stem cell (BMSC) osteogenesis mediated by RhoA/ROCK. Methods: BMSCs were cultured with and without DMOG and/or Y-27632 (ROCK1 inhibitor). Cell proliferation, alkaline phosphatase (ALP) levels, and calcium deposits were determined. The expression of Runx2, OSX, p-cofilin, RhoA, and GTP-bound RhoA was determined by real-time RT-PCR and Western blot. Rho-associated coiled-coil-containing protein kinase (ROCK) activity was determined by measuring the phosphorylation of myosin-binding subunit of myosin phosphatase using an ELISA kit. Actin morphology was observed by immunofluorescence. Results: After 24 h, DMOG (0.5 mM) increased the expression of GTP-bound RhoA (+141%, P < 0.001) and enhanced ROCK activity (315%, P < 0.001). DMOG (0.5 mM) enhanced ALP levels after 3, 7, and 21 days of osteogenic induction (all P < 0.001) and strengthened calcium deposition (P < 0.001). In addition, compared with controls, DMOG (0.5 mM) increased the mRNA levels of osteogenesis genes RUNX2 and OSX (all P < 0.001). Furthermore, compared with controls, DMOG increased the expression of p-cofilin (+57%, P < 0.001), which resulted in rearrangement of actin filaments. All these effects were abolished, at least in part, by Y-27632. Conclusion: DMOG promotes BMSC osteogenic differentiation via activation of RhoA/ROCK, suggesting clues for future therapies using BMSCs.
Introduction
Dimethyloxalylglycine (DMOG) is a prolyl hydroxylase inhibitor (PHI), which is a rate-limiting enzyme in the degradation of hypoxia inducible factor (HIF) [1] . Therefore, DMOG physiologically simulates low oxygen environment by blocking the degradation of HIF, and inducing chemical hypoxia [2, 3] . Approximately 100 downstream target genes of HIF are involved in cellular energy metabolism, ion metabolism, angiogenesis, cell differentiation, apoptosis, cellular proliferation, and migration [4, 5] . Zhou et al. reported that HIF-1α inhibited BMP2-induced stem cell osteogenesis [6] . Recent studies suggest that DMOG plays an important role in osteogenic differentiation, which is debatable. Indeed, Irwin et al. [7] showed that DMOG increased adipogenic gene expression and decreased osteoblastic genes. On the other hand, Woo et al. [8] reported that DMOG accelerated bone regeneration, which is supported by Peng et al. [9] showing that DMOG prevented bone loss after ovariectomy.
Previous studies demonstrated that RhoA/ROCK signaling pathway plays a key role in cellular processes including smooth muscle contraction, stress fiber formation, cell migration, cell division, cell adhesion, and cell differentiation by regulating the actin cytoskeleton [10] [11] [12] [13] [14] [15] . Previous studies showed that the RhoA/ROCK signaling pathway regulated osteogenesis. Indeed, Wang et al. [16] reported that bone morphogenic protein (BMP) promotes human mesenchymal stem cell (MSC) osteogenesis by altering cytoskeleton via activation of RhoA/ROCK signaling. Other studies showed that osteogenic growth peptide (OGP) [17] , connective tissue growth factor [18] , extracellular matrix [19] , and hydrostatic pressure [20] promote the osteogenic differentiation of human bone marrow MSC (BMSC) via RhoA/ROCK signaling activation.
In RhoA/ROCK signaling, GTP-bound RhoA activates Rho-associated coiled-coil-containing protein kinase (ROCK1), which phosphorylates the threonine of LIM kinase 1 (LIMK1) at positions 505 and 508. The phosphorylated LIMK inactivates cofilin by phosphorylating the serine of cofilin at position 3. Cofilin modulates actin rearrangement by truncating actin filaments and depolymerizing F-actin. However, phosphorylated cofilin (p-cofilin) has no effect on F-actin [21] [22] [23] [24] [25] .
Until now, the precise mechanism of DMOG in the regulation of MSC osteogenesis remains unclear. Understanding the specific cellular signaling pathways mediating DMOG-induced osteogenesis is an important step toward the regulation of MSC osteogenic differentiation and their clinical application. Vogel et al. [26] found that DMOG treatment of Hela cells or prolyl hydroxylase domain (PHD)-knockout HeLa cells activated RhoA/ROCK signaling independent of HIF by inhibiting PHD. The activation of RhoA/ROCK alters the cytoskeleton and cell migration.
Therefore, the aim of this study was to investigate the role of DMOG in BMSC osteogenesis and determine whether the altered cell shape following the activation of RhoA/ROCK signaling induced osteogenic differentiation of DMOG-induced MSCs.
Materials and Methods

Isolation, culture, and identification of BMSCs
Three-week-old male Kunming mice (n=20) weighing 18-20g were purchased from the experimental animal center of Kunming Medical University (Yunnan, China). BMSCs were isolated and cultured as previously described [27] . Briefly, mice bone marrow was collected by flushing the cavities of femurs and tibias with DMEM (GIBCO, Invitrogen Inc., Carlsbad, CA, USA). Whole bone marrow cells were seeded in 1×10 6 in culture flasks supplemented with DMEM and 10% fetal bovine serum (FBS) (Hyclone,Thermo Fisher Scientific, Waltham, MA, USA). The flasks were incubated with 5% CO 2 at 37°C. After 48 h, nonadherent cells were washed out. When the cells reached approximately 80% confluence, the cells were subcultured at 1:2 or 1:3. BMSCs were used after four to six passages.
Anti-CD90-FITC (Beckman-Coulter, Brea, CA, USA), anti-CD44-FITC (Beckman-Coulter), anti-CD105-PE (Beckman-Coulter), and anti-CD34-PC5 (Beckman-Coulter) antibodies were used for flow cytometry (EPICS-XL, Beckman Coulter). CD44+ CD90+ CD105+ CD34-cells were identified as BMSCs (CD90: 98.5%; CD105: 99.9%; CD44: 99.0%; CD34: 0.1%) (Fig. 1) .
BMSCs differentiated into osteoblasts using an osteogenic medium (10% FBS, low glucose DMEM, 50 μg/mL of vitamin C, 10 mmol/L of β-glycerophosphate, and 10 -8 mol/L of dexamethasone) [28] for 14 days. Calcium deposition was evaluated using an alizarin red solution ( Fig. 2A) .
BMSCs also differentiated into chondrocytes using a chondrogenic medium (10% FBS, low glucose DMEM, 5×10 -4 mol/L of IBMX, 2×10 -4 mol/L of indomethacin, 10 μg/mL of insulin, 10 -7 mol/L of dexamethasone, 6.25 mg/mL of transferrin, and 50 µg/mL of vitamin C) [29] for 14 days. Differentiation was evaluated by toluidine blue staining (Fig. 2B) .
BMSCs also differentiated into adipocytes using an adipogenic medium (10% FBS, high glucose DMEM, 5×10 -4 mol/L of IBMX, 2×10 -4 mol/L of indomethacin, 10 μg/ml of insulin, and 10 -6 mol/L of dexamethasone) [30] for 7 days. Lipid vesicles were identified by oil-red O staining (Fig. 2C) .
All the experiments were approved by the Animal Ethics Committee of Kunming Medical University. All efforts were made to minimize animal suffering and minimize the number of animals used.
Cell proliferation
Cell proliferation was estimated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. BMSCs at passage 5 were seeded on 96-well plates at 1×10 4 /mL (200 µL/well) in low-glucose DMEM and 10% FBS. They were treated with different concentrations (0, 0.1, 0.5, 1, and 2 mM) of DMOG (Cayman Chemical, Ann Arbor, MN, USA) for 24, 48, 72, and 96 h. After DMOG treatment, the cell culture medium was discarded and the cells were treated with 150 μL of MTT (5 mg/mL; Invitrogen Inc., Carlsbad, CA, USA) for 4 h. After careful removal of culture media, 150 μL of DMSO were added to fully dissolve the purple crystals by shaking for 10 min. The absorbance in each well was measured at 490 nm using Model 550 automatic microplate reader (Bio-Rad, Hercules, CA, USA).
Alkaline phosphatase levels
Alkaline phosphatase (ALP) levels were determined by colorimetry using an ALP assay kit (Jiancheng Bioengineering institute, Nanjing, China). BMSCs were seeded on 6-well plates at a density of 1×10 5 cells/ well, and treated with different concentrations (0, 0.1, 0.5, 1, and 2 mM) of DMOG in osteogenic medium for 3, 7, 14, and 21 days, osteogenic medium (control), osteogenic medium containing 0.5 mM of DMOG, osteogenic medium containing 10 μM of Y-27632 (ROCK inhibitor; Cayman Chemical, Ann Arbor, MN, USA), and osteogenic medium containing 0.5 mM of DMOG and 10 μM of Y-27632 for 3, 7, 14, and 21 days. After treatment, cells were lysed with RIPA buffer (Invitrogen Inc., Carlsbad, CA, USA) at 37°C for 15 min, and treated with the chromogenic agent provided by the kit. According to previous studies and our preexperiments, 10μM of Y-27632 was used to inhibit the activity of ROCK in our experiment [31] . A standard phenol solution replaced the cell lysis solution. The blank tube contained double-distilled water instead of cell lysis solution. The blank tube was used to adjust "zero". The absorbance in each tube was measured at 520 nm. ALP levels were determined as follows: ALP=(KingU/100mL)=(OD test tube /OD Standard tube )×0.005 mg×(100 mL/0.05 mL).
Real-time RT-PCR
BMSCs were treated with osteogenic medium (control), osteogenic medium containing 0.5 mM of DMOG, osteogenic medium containing 10 μM of Y-27632, or osteogenic medium containing 0.5 mM of DMOG and 10 μM of Y-27632 for 1, 3, and 7 days. BMSCs were harvested and the total RNA was isolated using TRIzol (Invitrogen Inc., Carlsbad, CA, USA). The 260/280 nm absorbance ratio was used to determine the purity and concentration of the RNA. The cDNA was synthesized using a SuperScript TM III First-Strand Synthesis System for RT-PCR (Invitrogen Inc., Carlsbad, CA, USA). The primer sequences were: Runx2, forward 5'-TTC AAC GAT CTG AGA TTT GTG GG-3' and reverse 5'-GGA TGA GGA ATG CGC CCT A-3'; Osterix, forward 5'-ATG GCG TCC TCT CTG CTT G-3' and reverse 5'-TGA AAG GTC AGC GTA TGG CTT-3'; and β-actin, forward 5'-GTG ACG TTG ACA TCC GTA AAG A-3' and reverse 5'-GCC GGA CTC ATC GTA CTC C-3'. Analysis was performed using an ABI prism 7000 real-time PCR system (Applied Biosystems, Foster City, CA, USA) and Platinum SYBR Green qPCR (Invitrogen Inc., Carlsbad, CA, USA). All reactions involved initial denaturation at 95°C for 2 min followed by 40 cycles of 95°C for 15 s, 54°C for 30 s, and 65°C for 20 s. The 2 -ΔΔCt method was used to represent the relative mRNA expression of target genes. β-actin was used as an internal control.
Western blot
BMSCs were treated with osteogenic medium (control), osteogenic medium containing 0.5 mM of DMOG, osteogenic medium containing 10 μM of Y-27632, or osteogenic medium containing 0.5 mM of DMOG and 10 μM of Y-27632 for 24h. BMSCs were harvested and lysed using RIPA buffer (Beyotime Biotechnology, Jiangsu, China). Protein levels in the supernatant were determined using the BCA Protein Assay Kit (Tiangen Biotech (Beijing) Co., Ltd., Beijing, China). Equal amounts of proteins (20 μg) were separated on 6-18% SDS-PAGE and transferred to PVDF membranes (Millipore corp., Billerica, MA, USA). The membranes were blocked with 5% skim milk for 1 h, and washed with TBST three times. The membranes were incubated with a primary antibody against p-cofilin (#3313; 1:1000; Cell Signaling, Danvers, MA, USA), RhoA(#05-778;1:1000; Millipore corp., Billerica, MA, USA ),GAPDH (#5174; 1:1000; Cell Signaling, Danvers, MA, USA), overnight at 4°C. The membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein expression signals were visualized by ECL (Beyotime Biotechnology, Jiangsu, China). Band intensity was quantified using the Image J software (National Institutes of Health, Bethesda, MD, USA).
RhoA activation assay
BMSCs were treated with osteogenic medium (control), osteogenic medium containing 0.5 mM of DMOG, osteogenic medium containing 10 μM of Y-27632, or osteogenic medium containing 0.5 mM of DMOG and 10 μM of Y-27632.Cells were harvested on day 1 and lysed with lysis buffer (Invitrogen Inc., Carlsbad, CA, USA). Twenty microliters of supernatant was used to determine the expression of total RhoA. The remaining supernatant was used to isolate GTP-bound RhoA using the Rho activation assay kit (Millipore corp., Billerica, MA, USA) according to the manufacturer's instructions. Briefly, supernatants were incubated with rhotekin-binding domain beads and glutathione S-transferase-Rho-binding domain of mouse rhotekin contained in the Rho Assay Reagent was combined with GTP-Rho. Later, the GTP-Rho was isolated.The GTPbound RhoA and RhoA were detected by Western blot using a monoclonal antibody to RhoA. The membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein expression signals were visualized by ECL (Beyotime Biotechnology, Jiangsu, China). Band intensity was quantified using the Image J software (National Institutes of Health, Bethesda, MD, USA).
ROCK activity assay
BMSCs were treated with osteogenic medium (control), osteogenic media containing 0.5 mM of DMOG, 10 μM of Y-27632, or 0.5 mM of DMOG and 10 μM of Y-27632 for 24 h. BMSCs were harvested and re-suspended with cell extraction buffer (Invitrogen Inc., Carlsbad, CA, USA). The re-suspended cells were lysed using three cycles of freezing and thawing. Cell lysates were centrifuged at 12000g for 10 min. Supernatants were obtained and the ROCK activity was measured using a Rho-kinase Assay Kit (Cyclex Co., Ltd, Nagano, Japan) according to the manufacturer's instructions. ROCK activity was expressed as milliunits per microgram of protein with Cyclex ROCK positive control as a reference.
Calcium deposition assay
Calcium deposition was qualitatively detected by alizarin red staining. Briefly, BMSCs were seeded at a density of 5×10 4 cells per well in 24-well plates, treated with osteogenic medium (control), osteogenic media containing 0.5 mM of DMOG, 10 μM of Y-27632, or 0.5 mM of DMOG and 10μM of Y-27632, and cultured for 21 days. Cells were fixed in 4% formaldehyde for 30 min. After washing with PBS three times, the cells were incubated in 0.1% alizarin red solution (Aladdin Chemicals Co., Ltd., Shanghai, China) for 10 min. Staining intensity was observed under an IX71 Inverted microscope (Olympus, Tokyo, Japan)
Calcium deposition was quantitatively detected by colorimetry using a calcium assay kit (Jiancheng Bioengineering institute, Nanjing, China). Briefly, the cells were rinsed with PBS and exposed to 0.5 mol/L hydrochloric acid (HCl) overnight. The cells were harvested and centrifuged at 12000g for 10 min.The supernatants were quantified spectrophotometrically at 610 nm by reacting with methylthymol blue complexone. Calcium concentration was calculated from the standard curve of serial dilutions of a calcium standard solution, and the values were normalized to DNA content (expressed in mg calcium/mg DNA). DNA assay was performed using FluoReporter Blue Fluorometric dsDNA Quantitation Kit (Molecular Probes,OR, USA) according to the manufacturer's instructions.
Immunofluorescence staining
BMSCs were seeded at a density of 5×10 4 cells per well in 6-well plates with osteogenic medium. After the cells were adherent, BMSCs were treated with osteogenic medium (control), osteogenic media containing 0.5 mM of DMOG, 10 μM of Y-27632, or 0.5 mM of DMOG and 10 μM of Y-27632 for 24 h. After treatment, cells were fixed with 4% paraformaldehyde for 30 min. Cells were washed with PBS and incubated with 0.1% Triton X-100 for 5 min. After washing, nonspecific binding was blocked by incubation with blocking solution (1% BSA in PBS) for 30 min. Cells were incubated with 5 μg/mL of FITC-labeled phalloidin (ENZO) overnight at 4°C in the dark. Cells were analyzed by 90I fluorescence microscopy (NIKON, Tokyo, Japan).
Statistical Analysis
The data was analyzed with SPSS 17.0 (IBM, Armonk, NY, USA). All the data are shown as mean ± standard deviation. Statistical significance was evaluated by one-way analysis of variance (ANOVA) with the Student-Newman-Keuls (SNK) test for post hoc analysis. Two-sided P-values < 0.05 were considered statistically significant.
Results
DMOG inhibited BMSC proliferation and promoted ALP levels during BMSC osteogenic differentiation
To determine the effect of DMOG on the proliferation of BMSCs, a MTT assay was performed. After 24 h and compared with the control group, 1 mM (-2.21%; P < 0.05) and 2 mM(-6.12%; P < 0.05) of DMOG inhibited BMSCs proliferation. BMSC proliferation was inhibited after 48, 72, and 96 h of treatment with 1 mM DMOG (48 h: -26.8%; 72 h: -40.2%; and 96 h: -63.5%; all P < 0.001) and 2 mM DMOG (48 h: -34.6%; -50.2%; and 96 h: -69.5%, all P < 0.001), compared with the control group (Fig. 3A) .
ALP is a key enzyme mediating osteogenesis. Pre-osteoblasts secrete ALP and promote calcium deposition during bone matrix mineralization [32] . ALP level in the control group was low. Compared with the control group, the DMOG group significantly increased the expression of ALP (all P < 0.001), with 0.5 mM DMOG showing the most potent effect at all time points (3 days: +626%; 7 days: +483%; 14 days: +352%; and 21 days: +278%, all P < 0.001) (Fig. 3B) . Therefore, 0.5 mM DMOG was selected for subsequent experiments.
DMOG promoted active-RhoA protein expression and increased ROCK activity, which was inhibited by Y-27632
Previous studies showed that RhoA/ROCK signaling played a key role in the regulation of osteogenesis [16] [17] [18] . Results showed that after 24 h of culture, 0.5 mM DMOG increased the expression of GTP-bound RhoA (P < 0.001 vs. control group). In addition, Y-27632 abolished the DMOG-mediated up-regulation of GTP-bound RhoA protein expressions (P < 0.001) (Fig. 4A) .
In order to determine the inhibitory effects of Y-27632 on ROCK activity, the ROCK activity assay was performed. Compared with the control group, the DMOG group showed a 315% increase in ROCK activity (P < 0.001), which was significantly reduced in the Y-27632 (-81.9%, P < 0.001) and DMOG+Y-27632 groups (-81.1%, P < 0.001) (Fig. 4B) .
DMOG increased ALP levels and calcium deposition during osteogenic differentiation, which were inhibited by Y-27632
In order to investigate the effects of DMOG on osteogenic differentiation and matrix mineralization of BMSCs, assays for ALP levels and Alizarin red staining for calcium deposits were used. Compared with the control group, 0.5 mM of DMOG enhanced ALP level after osteogenic induction (all P < 0.001) (Fig. 5) . The addition of Y-27632 reversed the effect of DMOG partially (all P < 0.001) (Fig. 5) . Calcium deposition was enhanced with 0.5 mM DMOG in 21d. However, the addition of Y-27632 partially reversed the calcium deposition induced by DMOG as visualized by alizarin red staining (Fig. 6A) . Quantification of calcium secretion on day 21 revealed that 0.5 mM DMOG enhanced calcium deposition after osteogenic induction (P < 0.001) (Fig. 6B) . Addition of Y-27632 partially reversed the calcium deposition induced by DMOG (P < 0.001) (Fig. 6B) .
DMOG up-regulated RUNX2 and osterix mRNA expression during osteogenic differentiation, which was inhibited by Y-27632
The transcription of osteogenic differentiation marker genes was investigated. RUNX2 and OSX are essential transcription factors that control the expression of osteogenic genes. Coinciding with ALP staining and alizarin red staining, 0.5 mM DMOG induced the mRNA levels of RUNX2 (all P < 0.001) and OSX compared with the controls (all P < 0.001) (Fig. 7A  and 7B ). The addition of Y-27632 partially reversed this increase (all P < 0.01) (Fig. 7A and  7B) .
DMOG promoted cytoskeletal alterations and p-cofilin expression during osteogenic differentiation, which were inhibited by Y-27632
Actin controls cytoskeletal network and cell morphology. Phalloidin inhibits F-actin depolymerization and upsets the balance between actin polymerization and depolymerization. Cofilin mediates actin depolymerization [33, 34] . The effects of 0.5 mM DMOG on BMSC actin cytoskeleton were determined using Western blot of p-cofilin, and FITC-labelled phalloidin staining. Compared with controls, DMOG increased the expression of p-cofilin (+57%, P < 0.001), while Y-27632 inhibited this increase partially (P < 0.001) ( Fig. 8A) . Treatment with 0.5 mM DMOG for 24 h led to rearrangement of actin filaments compared with controls (Fig. 8B) . These changes were abolished, at least in part, by Y-27632 treatment.
Discussion
DMOG regulates cell differentiation. However, the role of DMOG in osteogenic differentiation of BMSCs is still controversial. Therefore, this study investigated the effect of DMOG on BMSC osteogenesis. DMOG inhibited BMSC proliferation; enhanced ALP levels and calcium deposits after osteogenic induction; promoted the transcription of RUNX2 and OSX; and increased the expression of p-cofilin. In addition, actin cytoskeleton was rearranged. The results suggested that DMOG promoted BMSC osteogenesis.
In the present study, 0.5 mM DMOG was the optimal concentration necessary to induce BMSCs osteogenesis. Schultz et al. [35] found that 100 μM DMOG inhibited the proliferation of vascular smooth muscle cells. Chung et al. [36] found that 125 μM DMOG inhibited prostate cancer cell proliferation and 1000 μM DMOG inhibited prostate cancer cell proliferation. Marchbank et al. [37] found that 10-70 μM DMOG promoted HT29 cell proliferation and 70-120 μM DMOG inhibited HT29 cell proliferation. Indeed, PHI can be divided into two groups: iron chelator and ketoglutaric acid analogues [38] . Previous studies showed that the effects of different PHIs on cell proliferation varied. Similar PHI also showed varying effects on cell proliferation in different studies. In addition, these studies used a number of different cell types. Therefore, additional studies are needed to elucidate the effects of DMOG on the osteogenesis of BMSCs.
The present study showed that DMOG increased osteogenic differentiation of BMSCs. Similarly, Irwin et al. [7] found that 5 mM DMOG inhibited BMSCs osteogenic differentiation and their adipogenic differentiation. Woo et al. [8] showed that DMOG promoted osteogenesis and bone regeneration in vivo. Peng et al. [9] indicated that DMOG prevented bone loss in ovariectomized C57BL/6J mice via enhanced angiogenesis and osteogenesis. Different mechanisms may mediate osteogenic differentiation of cells induced by different PHI, or different concentrations of specific PHI may affect osteogenesis differently. Additional studies are needed to address these issues.
RUNX2 (also named core binding factor-α1, Cbfα1) is expressed by BMSCs during embryonic development. It plays an important role in BMSCs osteogenic regulation [39] . Previous in vitro studies showed that RUNX2 promoted osteogenesis-related gene expression such as type I collagen, osteopontin, bone sialoprotein, and osteocalcin [40, 41] . RUNX2 activation also mediated BMP9-induced C3H10T1/2 osteogenesis [42] . OSX is an osteogenic-specific transcription factor [43] . The cartilage of OSX-deficient mice developed without bone formation, indicating that endochondral ossification and intra-membranous ossification were inhibited [44] . In OSX-deficient mice, the expression of RUNX2 is normal while the expression of OSX is blocked after RUN2 silencing [43] . The OSX promoter contains the RUNX2-binding domain [45] . However, the genes downstream of OSX are still unclear. Intermittent stretching was found to promote BMSCs OSX mRNA expression, while OSX silencing was found to inhibit BMSCs osteogenesis [46] . In the present study, DMOG promoted the transcription of RUNX2 and OSX.
RhoA belongs to the Ras GTPase super-family. It plays an important regulatory role in cell morphology, actin rearrangement, activation of MAPK signaling, cell cycle, gene transcription, cell migration and adhesion [21, 23, 47, 48] . ROCK is the main downstream substrate of Rho. ROCK has two subtypes: ROCK1 and ROCK2 [49, 50] . RhoA-GTPase acts as a molecular switch. RhoA-bound GTP is active [51] . ROCK phosphorylates the cytoskeletal protein regulators, playing an important role in actin cytoskeleton [21, 23] . In the present study, DMOG promoted BMSC osteogenesis, which was abrogated, at least in part, by Y-27632, a ROCK1 inhibitor, suggesting Rho/ROCK signaling. Other signal transduction pathways may also mediate MSCs osteogenesis. Tang et al. reported that lithium chloride controlled the differentiation of BMSCs directly via Wnt and Hh pathways [52] . Decreased pHi induced by cariporide promoted human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)-induced osteogenesis [53] . Silencing of the calcium-binding protein S100A6 expression increased osteogenic differentiation, while S100A6 overexpression inhibited osteogenic differentiation [54] .
Novel strategies to promote osteogenesis are important, particularly in diseases associated with an imbalance of osteoblasts and adipocytes in bone marrow like steroidinduced avascular necrosis of the femoral head (SANFH) [55] . DMOG regulates the differentiation of osteoblastic and adipogenic lineage. Its therapeutic role in early-stage SANFH still requires robust clinical evidence. Additional studies are needed to determine whether BMSCs survive transplantation and whether they are the best source of stem cells
